YME1L1 and acute kidney injury: In conclusion, the present study reveals YME1L1‐mediated modulation of mitochondrial energy metabolism, identifies the downregulation of YME1L1 as a contributor to AKI, and illuminates the underlying mechanism that transcriptional factor SREBP1c mediates cisplatin‐induced suppression of YME1L1 via direct combining with its promoter domain.